E-viri
Recenzirano
Odprti dostop
-
Deek, Matthew P; Van der Eecken, Kim; Sutera, Philip; Deek, Rebecca A; Fonteyne, Valérie; Mendes, Adrianna A; Decaestecker, Karel; Kiess, Ana Ponce; Lumen, Nicolaas; Phillips, Ryan; De Bruycker, Aurélie; Mishra, Mark; Rana, Zaker; Molitoris, Jason; Lambert, Bieke; Delrue, Louke; Wang, Hailun; Lowe, Kathryn; Verbeke, Sofie; Van Dorpe, Jo; Bultijnck, Renée; Villeirs, Geert; De Man, Kathia; Ameye, Filip; Song, Daniel Y; DeWeese, Theodore; Paller, Channing J; Feng, Felix Y; Wyatt, Alexander; Pienta, Kenneth J; Diehn, Maximillian; Bentzen, Soren M; Joniau, Steven; Vanhaverbeke, Friedl; De Meerleer, Gert; Antonarakis, Emmanuel S; Lotan, Tamara L; Berlin, Alejandro; Siva, Shankar; Ost, Piet; Tran, Phuoc T
Journal of clinical oncology, 10/2022, Letnik: 40, Številka: 29Journal Article
JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within , / , , or . The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio HR, 0.44; 95% CI, 0.29 to 0.66; value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.